- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- July 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- July 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- April 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- January 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- November 2025
- 220 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- November 2025
- 178 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- November 2025
- 182 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Report
- October 2025
- 196 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- October 2025
- 183 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- November 2025
- 276 Pages
Global
From €5249EUR$5,850USD£4,607GBP
- Clinical Trials
- July 2025
- 450 Pages
Global
From €3589EUR$4,000USD£3,150GBP
€4487EUR$5,000USD£3,938GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1436EUR$1,600USD£1,260GBP
€1795EUR$2,000USD£1,575GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1077EUR$1,200USD£945GBP
€1346EUR$1,500USD£1,181GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2154EUR$2,400USD£1,890GBP
€2692EUR$3,000USD£2,363GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2154EUR$2,400USD£1,890GBP
€2692EUR$3,000USD£2,363GBP

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more